![Exploring the Serene Beauty of Nature: A Reflection on [YouTube video title]](https://cavemangardens.art/storage/2024/04/114803-exploring-the-serene-beauty-of-nature-a-reflection-on-youtube-video-title-360x180.jpg)
Nkarta is charting a course for its allogeneic chimeric antigen receptor (CAR) natural killer cell (NK) treatment in autoimmune lupus nephritis after getting approval from the United States Food and Drug Administration (FDA) to check NKX019. The cell treatment professional ends up being the 2nd to get FDA consent for an NK item in a persistent autoimmune illness, following Artiva Biotherapeutics’ AlloNK. In August 2023 that cord-blood-derived treatment was authorized for screening in mix with rituximab, likewise in lupus nephritis.
Gain access to alternatives
Gain access to Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access membership
24,99 EUR / 30 days
cancel at any time
Sign up for this journal
Get 12 print concerns and online gain access to
206,07 EUR each year
just 17,17 EUR per concern
Lease or purchase this short article
Rates differ by short article type
from$1.95
to$39.95
Costs might go through regional taxes which are determined throughout checkout
Rights and approvals
About this short article
Mention this short article
NKs for lupus poised for trial.
Nat Biotechnol 411496 (2023 ). https://doi.org/10.1038/s41587-023-02043-9
-
Released:
-
Concern Date:
-
DOI: https://doi.org/10.1038/s41587-023-02043-9
Discover more from CaveNews Times
Subscribe to get the latest posts sent to your email.
